TY - JOUR
T1 - 17α-hydroxyprogesterone caproate for the prevention of preterm delivery
T2 - A cost-effectiveness analysis
AU - Odibo, Anthony O.
AU - Stamilio, David M.
AU - Macones, George A.
AU - Polsky, Daniel
PY - 2006/9
Y1 - 2006/9
N2 - To evaluate whether the use of 17α-hydroxyprogesterone caproate for the prevention of recurrent preterm deliveries is cost-effective. Using decision-analysis modeling, we compared the cost-effectiveness of using 17α-hydroxyprogesterone caproate in four subgroups: 1) Prior preterm deliveries less than 32 weeks; 2) prior preterm deliveries 32-37 weeks; 3) prior term delivery; and 4) no prior delivery. Each subgroup was compared with a “no treatment” group. Costs included those for 17α-hydroxyprogesterone caproate, hospital admissions, and complications from preterm deliveries. The main outcome measures include cost per quality-adjusted life-year gained and the number of preterm deliveries prevented. Secondary outcomes include neonatal complications prevented. One-way and multiway sensitivity analyses were performed. The use of 17α-hydroxyprogesterone caproate for the prevention of preterm deliveries result in cost-savings in women with prior preterm deliveries less than 32 weeks and 32-37 weeks. The sensitivity analyses revealed the model to be robust over a wide range of values for evaluated variables. Within our baseline assumptions, 17α-hydroxyprogesterone caproate was associated with cost-savings when used for the prevention of preterm deliveries in women with prior preterm deliveries. II-3.
AB - To evaluate whether the use of 17α-hydroxyprogesterone caproate for the prevention of recurrent preterm deliveries is cost-effective. Using decision-analysis modeling, we compared the cost-effectiveness of using 17α-hydroxyprogesterone caproate in four subgroups: 1) Prior preterm deliveries less than 32 weeks; 2) prior preterm deliveries 32-37 weeks; 3) prior term delivery; and 4) no prior delivery. Each subgroup was compared with a “no treatment” group. Costs included those for 17α-hydroxyprogesterone caproate, hospital admissions, and complications from preterm deliveries. The main outcome measures include cost per quality-adjusted life-year gained and the number of preterm deliveries prevented. Secondary outcomes include neonatal complications prevented. One-way and multiway sensitivity analyses were performed. The use of 17α-hydroxyprogesterone caproate for the prevention of preterm deliveries result in cost-savings in women with prior preterm deliveries less than 32 weeks and 32-37 weeks. The sensitivity analyses revealed the model to be robust over a wide range of values for evaluated variables. Within our baseline assumptions, 17α-hydroxyprogesterone caproate was associated with cost-savings when used for the prevention of preterm deliveries in women with prior preterm deliveries. II-3.
UR - http://www.scopus.com/inward/record.url?scp=33748375575&partnerID=8YFLogxK
U2 - 10.1097/01.AOG.0000232503.92206.d8
DO - 10.1097/01.AOG.0000232503.92206.d8
M3 - Article
C2 - 16946206
AN - SCOPUS:33748375575
SN - 0029-7844
VL - 108
SP - 492
EP - 499
JO - Obstetrics and gynecology
JF - Obstetrics and gynecology
IS - 3
ER -